Zetrinal (Tablets, Syrup) Instructions for Use
ATC Code
R06AE07 (Cetirizine)
Active Substance
Cetirizine (Rec.INN WHO registered)
Clinical-Pharmacological Group
Histamine H1-receptor blocker. Antiallergic drug
Pharmacotherapeutic Group
H1 histamine receptor blocker
Pharmacological Action
A third-generation histamine H1-receptor blocker. It affects the “early” stage of the allergic reaction and reduces eosinophil migration; it limits the release of mediators at the “late” stage of the allergic reaction.
It has practically no anticholinergic or antiserotonin action. At therapeutic doses, it does not cause a sedative effect.
Pharmacokinetics
It is rapidly absorbed from the gastrointestinal tract. Cmax after oral administration is reached within 1 hour. The bioavailability of cetirizine when taken as tablets and syrup is the same. Food does not affect the completeness of absorption (AUC), but prolongs the time to reach Cmax by 1 hour and reduces the value of Cmax by 23%.
When taken at a dose of 10 mg once a day for 10 days, Css in plasma is 310 ng/ml and is noted 0.5-1.5 hours after administration. Plasma protein binding is 93% and does not change with cetirizine concentrations in the range of 25-1000 ng/ml. The pharmacokinetic parameters of cetirizine change linearly when prescribed in doses of 5-60 mg. Vd is 0.5 l/kg.
It is metabolized in the liver in small amounts by O-dealkylation to form a pharmacologically inactive metabolite (unlike other H1-histamine receptor antagonists, which are metabolized in the liver by the cytochrome system). It does not accumulate. Two-thirds of the dose is excreted unchanged by the kidneys and about 10% in the feces. Systemic clearance is 53 ml/min. T1/2 in adults is 7-10 hours, in children aged 6 to 12 years – 6 hours, from 2 to 6 years – 5 hours, from 6 months to 2 years – 3.1 hours.
In elderly patients, T1/2 increases by 50%, and systemic clearance decreases by 40% (due to decreased renal function). In patients with impaired renal function (creatinine clearance <40 ml/min), the clearance of the drug decreases and T1/2 is prolonged (for example, in patients on hemodialysis, total clearance decreases by 70% and is 0.3 ml/min/kg, and T1/2 is prolonged 3 times), which requires an appropriate change in the dosage regimen.
It is practically not removed during hemodialysis. In patients with chronic liver diseases (hepatocellular, cholestatic or biliary cirrhosis), an increase in T1/2 by 50% and a decrease in total clearance by 40% are noted (dose adjustment is required only with a concomitant decrease in glomerular filtration rate). It penetrates into breast milk.
Indications
Hay fever; allergic rhinitis, conjunctivitis, dermatitis; urticaria, angioedema.
ICD codes
| ICD-10 code | Indication |
| H10.1 | Acute atopic (allergic) conjunctivitis |
| J30.1 | Allergic rhinitis due to pollen |
| J30.3 | Other allergic rhinitis (perennial allergic rhinitis) |
| L20.8 | Other atopic dermatitis (neurodermatitis, eczema) |
| L23 | Allergic contact dermatitis |
| L24 | Irritant contact dermatitis |
| L28.0 | Lichen simplex chronicus (circumscribed neurodermatitis) |
| L50 | Urticaria |
| T78.3 | Angioneurotic edema (Quincke's edema) |
| ICD-11 code | Indication |
| 9A06.70 | Atopic eczema of the eyelids |
| 9A60.01 | Acute atopic conjunctivitis |
| 9A60.02 | Allergic conjunctivitis |
| 9A60.0Y | Other specified papillary conjunctivitis |
| 9A60.0Z | Papillary conjunctivitis, unspecified |
| CA08.00 | Allergic rhinitis due to pollen |
| CA08.03 | Other allergic rhinitis |
| EA80.0 | Infantile atopic eczema |
| EA80.1 | Childhood atopic eczema |
| EA80.2 | Adult atopic eczema |
| EA80.Z | Atopic eczema, unspecified |
| EA83.00 | Lichen simplex of vulva |
| EA83.01 | Lichen simplex of male genital organs |
| EA83.02 | Lichen simplex of perianal area |
| EA83.0Z | Lichen simplex of unspecified location |
| EA85.20 | Atopic hand eczema |
| EB04 | Idiopathic angioedema |
| EK00.Z | Allergic contact dermatitis, unspecified |
| EK02.Z | Irritant contact dermatitis, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer the recommended adult and adolescent dose (12 years and older) as 10 mg once daily.
For children aged 6 to 12 years, administer 10 mg once daily or 5 mg twice daily.
For children aged 2 to 6 years, administer 5 mg once daily or 2.5 mg twice daily.
For pediatric patients aged 1 to 2 years, administer a dose of 2.5 mg once daily; dose may be increased to 2.5 mg twice daily in selected cases.
For infants aged 6 to 12 months, administer a dose of 2.5 mg once daily.
Adjust the dosage regimen for patients with renal impairment based on creatinine clearance.
For patients with moderate renal impairment (CrCl 30-49 ml/min), administer 5 mg once daily.
For patients with severe renal impairment (CrCl 10-29 ml/min), administer 5 mg every other day.
Do not administer to patients with end-stage renal disease (CrCl <10 ml/min).
Adjust dosage for patients with hepatic impairment only if concomitant renal impairment is present.
For elderly patients with normal renal function, no dose adjustment is required.
Take the tablet or syrup with or without food.
Adverse Reactions
Possible dry mouth, drowsiness, headache, fatigue.
Rarely skin manifestations of allergic reactions, angioedema.
In isolated cases dyspepsia, agitation.
Contraindications
Renal failure, pregnancy, lactation period, hypersensitivity to cetirizine.
Use in Pregnancy and Lactation
Contraindicated for use during pregnancy and lactation.
Use in Renal Impairment
Contraindicated in renal failure.
Cetirizine should be prescribed with caution to patients with chronic renal failure (moderate and severe – dose adjustment is required).
Pediatric Use
Cetirizine should be prescribed with caution to children (experience of use in children under 1 year of age is insufficient).
Geriatric Use
Cetirizine should be prescribed with caution to elderly patients (a decrease in glomerular filtration is possible).
Elderly patients with normal renal function do not require dose adjustment.
Special Precautions
Cetirizine should be prescribed with caution to patients with chronic renal failure (moderate and severe – dose adjustment is required), and to elderly patients (a decrease in glomerular filtration is possible).
Elderly patients with normal renal function do not require dose adjustment.
Use in pediatrics
Cetirizine should be prescribed with caution to children (experience of use in children under 1 year of age is insufficient).
Influence on the ability to drive vehicles and mechanisms
When the dose exceeds 10 mg/day, the ability for rapid reactions may deteriorate. During the treatment period, it is necessary to refrain from engaging in potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
Drug Interactions
No pharmacokinetic interaction was found with pseudoephedrine, cimetidine, ketoconazole, erythromycin, azithromycin, diazepam, and glipizide.
Concomitant administration with theophylline (400 mg/day) led to a 16% decrease in the total clearance of cetirizine (the kinetics of theophylline did not change).
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Film-coated tablets, 10 mg: 10, 20 or 30 pcs.
Marketing Authorization Holder
Abdi Ibrahim Ilac Sanayi ve Tic., A.S. (Turkey)
Dosage Form
| Zetrinal | Film-coated tablets, 10 mg: 10, 20 or 30 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets white or almost white, oblong, with a score on both surfaces.
| 1 tab. | |
| Cetirizine dihydrochloride | 10 mg |
Excipients: corn starch, lactose, polyvinylpyrrolidone K-30, magnesium stearate.
Shell composition: Eudragit E, titanium dioxide, polyethylene glycol 6000, talc.
10 pcs. – blisters (2) – cardboard packs.
Syrup 5 mg/5 ml: bottle 100 ml or 200 ml with measuring spoon included
Marketing Authorization Holder
Abdi Ibrahim Ilac Sanayi ve Tic., A.S. (Turkey)
Dosage Form
| Zetrinal | Syrup 5 mg/5 ml: bottle 100 ml or 200 ml with measuring spoon included |
Dosage Form, Packaging, and Composition
Syrup in the form of a clear liquid with a characteristic odor.
| 5 ml | |
| Cetirizine dihydrochloride | 5 mg |
Excipients: propylparahydroxybenzoate (nipasol), methylparahydroxybenzoate (nipagin), propylene glycol, sorbitol, acetic acid, glycerol, sodium saccharin, banana flavor, sodium acetate, purified water.
100 ml – bottles (1) complete with a 5 ml measuring spoon – cardboard packs.
200 ml – bottles (1) complete with a 5 ml measuring spoon – cardboard packs.
Mildronate capsules 500mg, 90pcs
Fenotropil pills 100mg, 60pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Kagocel pills 12mg, 30pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Noopept, pills 10mg, 50pcs
Picamilon pills 50mg, 60pcs
OKI, sachets 80mg 2g, 12pcs
Actovegin pills 200mg, 50pcs
Phenibut-Vertex pills 250mg, 20pcs
Cortexin, 10mg, 5ml, 10pcs
Nootropil pills 800mg, 30pcs
Arbidol, capsules 100mg, 40pcs 